Drug Trial Radar · NCT07649265
A Trial in Healthy Adult Participants and Adults With Autoimmune Diseases to Test How HBM7020 is Tolerated and How it Behaves in the Body
Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
63
Planned (sponsor's estimate)
Start
Sep 24, 2026
Primary completion
Nov 20, 2028
Study completion Nov 20, 2028
Sponsor
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
- Sponsor type
- Industry
- First posted
- Jun 16, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This first-in-human study evaluates the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of HBM7020. The study will enroll healthy participants at low doses, followed by participants with moderate to severe autoimmune diseases with predominant B-cell involvement. Eligible participants include patients with systemic lupus erythematosus (SLE), systemic sclerosis (SSc), Sjögren's disease (SjD), and rheumatoid arthritis (RA).
Conditions
- Rheumatoid Arthritis
- Systemic Lupus Erythematosus
- Systemic Sclerosis
- Sjögren's Disease
Interventions
HBM7020Drug
Liquid formulation, administered through intravenous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Study Discontinuations Due to Adverse Events Through Week 48Time frame: Up to Week 48
- Number of Participants With Signs Characteristic of Cytokine Release Syndrome (CRS), Immune Related Reaction (IRR), Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), Including Immunosuppression-Related InfectionTime frame: Up to Week 24
- Number of Participants With Dose limiting AE Evaluation During Dose EscalationTime frame: Up to Day 15
- Number of Participants With Clinically Significant Changes in Vital SignsTime frame: Up to Week 24
- Number of Participants With Clinically Significant Changes in Physical Examination FindingsTime frame: Up to Week 24
- Change From Baseline in Serum High Sensitivity C-Reactive Protein (hsCRP)Time frame: Up to Week 20
- Change From Baseline in Serum Erythrocyte Sedimentation Rate (ESR)Time frame: Up to Week 20
- Change From Baseline in Serum FerritinTime frame: Up to Week 20
- Change From Baseline in Serum Immunoglobulin G (IgG)Time frame: Up to Week 20
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Q-Pharm Pty Ltd
Brisbane, Queensland, Australia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.